Fludarabine with cyclophosphamide and mitoxantrone (FCM) in resistant or relapsed chronic lymphocytic leukemia (CLL):: Final results of a phase II study.

被引：0
|
作者：
Bosch, F
Ferrer, A
López-Guillermo, A
Giné, E
Cobo, F
Perales, M
Esteve, J
Villamor, N
Colomer, D
Bellosillo, B
Ribera, JM
Altes, A
Besalduch, J
Montserrat, E
机构：
[1] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain
[2] Hosp Sarit Pau, Dept Hematol, Barcelona, Spain
[3] Hosp Germans Trias & Pujol, Dept Hematol, Badalona, Spain
[4] Hosp Son Dureta, Dept Hematol, Palma de Mallorca, Spain
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2655
引用
收藏
页码：634A / 634A
页数：1
相关论文
共 50 条
  • [21] Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG)
    Koeppler, Hubert
    Fuss, Harald
    Hurtz, Hans J.
    Knigge, Owe
    Losem, Christoph
    Reschke, Daniel
    Schmitz, Stephan
    Weide, Rudolf
    Weiss, Johann
    Hallek, Michael
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (02) : 238 - 241
  • [22] Fludarabine (FAMP) and cyclophosphamide (CTX) therapy in chronic lymphocytic leukemia (CLL).
    OBrien, S
    Kantarjian, H
    Beran, M
    Freireich, E
    Komblau, S
    Koller, C
    Lerner, S
    Gilbreath, J
    Keating, M
    BLOOD, 1996, 88 (10) : 1910 - 1910
  • [23] Fludarabine versus fludarabine plus epirubicin in the treatment of chronic lymphocytic leukemia - Final results of a German Randomized phase-III study.
    Rummel, MJ
    Stilgenbauer, S
    Gamm, H
    Rost, A
    Hartmut, D
    Hoelzer, D
    Bergmann, L
    BLOOD, 2005, 106 (11) : 600A - 600A
  • [24] Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)
    Wendtner, Clemens
    Hillmen, Peter
    Mahadevan, Daruka
    Stilgenbauer, Stephan
    Uharek, Lutz
    Coutre, Steven
    Frankfurt, Olga
    Bloor, Adrian
    Bosch, Francesc
    Furman, Richard R.
    Kimby, Eva
    Gribben, John G.
    Gobbi, Marco
    Dreisbach, Luke
    Hurd, David Duane
    Sekeres, Mikkael A.
    Ferrajoli, Alessandra
    Shah, Sheetal
    Zhang, Jennie
    de Parseval, Laure Moutouh
    Chanan-Khan, Asher A.
    BLOOD, 2010, 116 (21) : 591 - 592
  • [25] Fludarabine versus fludarabine plus epirubicin in the treatment of chronic lymphocytic leukemia (CLL) - Preliminary results of a randomized phase-III multicenter study.
    Rummel, MJ
    Stilgenbauer, S
    Gamm, H
    Rost, A
    Doehner, H
    Hoelzer, D
    Bergmann, L
    BLOOD, 2002, 100 (11) : 384A - 384A
  • [26] Preliminary results of the combination rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) followed by rituximab maintenance in previously untreated chronic lymphocytic leukemia
    Bosch, Francesc
    Muntanola, Ana
    Villamor, Neus
    Terol, Maria Jose
    Gonzalez-Barca, Elena
    Ribera, Josep Maria
    Gonzalez, Marcos
    Abella, Eugenia
    Delgado, Julio
    Carbonell, Felix
    Garcia-Marco, Jose A.
    Escoda, Lourdes
    Ferrer, Secundino
    Monzo, E.
    Gonzalez, Yolanda
    Abrisqueta, Pau
    Salamero, Olga
    Gine, Eva
    Montserrat, Emili
    BLOOD, 2007, 110 (11) : 193A - 193A
  • [27] Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
    Wierda, W
    O'Brien, S
    Wen, S
    Faderl, S
    Garcia-Manero, G
    Thomas, D
    Do, KA
    Cortes, J
    Koller, C
    Beran, M
    Ferrajoli, A
    Giles, F
    Lerner, S
    Albitar, M
    Kantarjian, H
    Keating, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4070 - 4078
  • [28] NCRI CLL201 trial: A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL
    Hillmen, Peter
    Pocock, Christopher
    Cohen, Dena
    Cocks, Kim
    Sayala, Hazem A.
    Rawstron, Andy
    Kennedy, Daniel B.
    Fegan, Christopher
    Milligan, Don W.
    Dearden, Claire
    Smith, Alexandra
    Lindop, Emma
    Pettitt, Andrew R.
    BLOOD, 2007, 110 (11) : 231A - 232A
  • [29] NCRI CLL201 Trial: a randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL
    Hillmen, P.
    Pocock, C.
    Cohen, D.
    Gregory, W.
    Cocks, K.
    Rawstron, A. C.
    Kennedy, D. B.
    Fegan, C.
    Milligan, D.
    Dearden, C.
    Smith, A.
    Lindop, E.
    Pettitt, A. R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 119 - 120
  • [30] Role of ofatumumab (OFA) maintenance treatment in relapsed chronic lymphocytic leukemia (CLL): Final analysis of PROLONG study.
    Van Oers, Marinus
    Smolej, Lukas
    Petrini, Mario
    Offner, Fritz
    Grosicki, Sebastian
    Levin, Mark-David
    Davis, Jaclyn
    Stefanelli, Tommaso
    Banerjee, Hiya
    Hoever, Petra
    Geisler, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345